General Information
Regeneron OA Knee/Hip R475-OA-1688
A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and NSAID-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip.
| Protocol | R475-OA-1688 |
|---|---|
| Identifier | |
| UID | 4f3b6afb-19fc-47c0-8365-5ae6e3811795 |
| Status | Done - Archived |
| Phase | 3 |
| Category | Osteoarthritis/Knee / Adult |
| Launch Year | 2018 |
| NCT Number | - |
| Created | 2017-09-08 10:20 |
| Last Updated | 2017-09-08 10:20 |
Description
No description provided.
Comment
PCRS
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2019-05-17 | No |
| Enrollment Open | 2018-03-01 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | No | |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2020-01-13 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Regeneron Pharmaceuticals, Inc. |
|---|---|
| Division | Regeneron Pharmaceuticals |
| Team | Regeneron Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ICON Clinical Research, LLC |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
